Q BIOMED INC.: 10-Q filed 2018-10-19
What Q BIOMED INC. reported in its quarterly report filed 2018-10-19 (fiscal Q3 2018): 19 published measures, 45 facts as tagged in accession 0001654954-18-011384.
This filing
- Form
- 10-Q (quarterly report)
- Filed
- 2018-10-19
- Fiscal period
- fiscal Q3 2018
- Accession
- 0001654954-18-011384 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Q BIOMED INC. filings.
Reported measures
Total assets
Resources recognized on the balance sheet. Book assets are not the market value of the business.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2018-08-31 | 789,352 | USD | |
| At 2017-11-30 | 827,283 | USD |
Total liabilities
Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2018-08-31 | 707,054 | USD | |
| At 2017-11-30 | 471,039 | USD |
Stockholders equity
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2018-08-31 | 82,298 | USD | |
| At 2017-11-30 | 356,244 | USD |
Cash and cash equivalents
Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2018-08-31 | 786,852 | USD | |
| At 2017-11-30 | 824,783 | USD | |
| At 2017-08-31 | 2,499,169 | USD |
Net income or loss
Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2018-06-01 to 2018-08-31 | -2,985,531 | USD | 92 |
| 2017-12-01 to 2018-08-31 | -7,172,514 | USD | 274 |
| 2017-06-01 to 2017-08-31 | -3,981,397 | USD | 92 |
| 2016-12-01 to 2017-08-31 | -10,367,544 | USD | 274 |
Operating cash flow
Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2017-12-01 to 2018-08-31 | -4,983,182 | USD | 274 |
| 2016-12-01 to 2017-08-31 | -3,923,455 | USD | 274 |
Financing cash flow
Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2017-12-01 to 2018-08-31 | 4,945,251 | USD | 274 |
| 2016-12-01 to 2017-08-31 | 4,953,900 | USD | 274 |
Retained earnings or deficit
Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2018-08-31 | -30,015,884 | USD | |
| At 2017-11-30 | -22,843,370 | USD |
Current assets
Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2018-08-31 | 789,352 | USD | |
| At 2017-11-30 | 827,283 | USD |
Interest expense
Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2017-06-01 to 2017-08-31 | 202,160 | USD | 92 |
| 2016-12-01 to 2017-08-31 | 635,267 | USD | 274 |
Current liabilities
Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2018-08-31 | 707,054 | USD | |
| At 2017-11-30 | 471,039 | USD |
Operating expenses
Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2018-06-01 to 2018-08-31 | 2,985,531 | USD | 92 |
| 2017-12-01 to 2018-08-31 | 7,172,514 | USD | 274 |
| 2017-06-01 to 2017-08-31 | 3,735,984 | USD | 92 |
| 2016-12-01 to 2017-08-31 | 8,418,889 | USD | 274 |
Research and development expense
Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2018-06-01 to 2018-08-31 | 989,140 | USD | 92 |
| 2017-12-01 to 2018-08-31 | 2,624,753 | USD | 274 |
| 2017-06-01 to 2017-08-31 | 697,966 | USD | 92 |
| 2016-12-01 to 2017-08-31 | 2,296,324 | USD | 274 |
Common shares outstanding
Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2018-08-31 | 14,077,312 | shares | |
| At 2017-11-30 | 12,206,409 | shares |
Additional paid-in capital
Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2018-08-31 | 30,084,105 | USD | |
| At 2017-11-30 | 23,187,408 | USD |
Profit or loss including noncontrolling interests
Net income or loss including the portion attributable to noncontrolling interests. It can differ from the net income attributable to the parent that per-share figures use.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2017-12-01 to 2018-08-31 | -7,172,514 | USD | 274 |
Net income available to common stockholders
Net income after preferred dividends and similar adjustments, the numerator for basic earnings per share. It can be lower than reported net income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2017-12-01 to 2018-08-31 | 2,200,000 | USD | 274 |
General and administrative expense
General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2018-06-01 to 2018-08-31 | 1,996,391 | USD | 92 |
| 2017-12-01 to 2018-08-31 | 4,547,761 | USD | 274 |
| 2017-06-01 to 2017-08-31 | 3,038,018 | USD | 92 |
| 2016-12-01 to 2017-08-31 | 6,122,565 | USD | 274 |
Change in accounts payable
The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2017-12-01 to 2018-08-31 | 236,015 | USD | 274 |
| 2016-12-01 to 2017-08-31 | -115,881 | USD | 274 |
Inspect the source
- Entity
- Q BIOMED INC. / CIK 0001596062
- Captured
- SEC response SHA-256
f89c4e51720d8de34ddffc303f833ea01697bd4742662935a9f3cf09e3e7efbc
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001596062.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))